These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 29296720)

  • 1. X-ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors.
    Law RHP; Wu G; Leung EWW; Hidaka K; Quek AJ; Caradoc-Davies TT; Jeevarajah D; Conroy PJ; Kirby NM; Norton RS; Tsuda Y; Whisstock JC
    Blood Adv; 2017 May; 1(12):766-771. PubMed ID: 29296720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting subsite interactions of plasmin with substrates and inhibitors through computational docking analysis.
    Gohda K; Teno N; Wanaka K; Tsuda Y
    J Enzyme Inhib Med Chem; 2012 Aug; 27(4):571-7. PubMed ID: 21992704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A selective plasmin inhibitor, trans-aminomethylcyclohexanecarbonyl-L-(O-picolyl)tyrosine-octylamide (YO-2), induces thymocyte apoptosis.
    Lee E; Enomoto R; Takemura K; Tsuda Y; Okada Y
    Biochem Pharmacol; 2002 Apr; 63(7):1315-23. PubMed ID: 11960608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
    Rester U; Bode W; Moser M; Parry MA; Huber R; Auerswald E
    J Mol Biol; 1999 Oct; 293(1):93-106. PubMed ID: 10512718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of plasmin with tranexamic acid and alpha 2 plasmin inhibitor in the plasma and clot.
    Takada A; Ito T; Takada Y
    Thromb Haemost; 1980 Feb; 43(1):20-3. PubMed ID: 6447383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active site-directed plasmin inhibitors: Extension on the P2 residue.
    Hidaka K; Gohda K; Teno N; Wanaka K; Tsuda Y
    Bioorg Med Chem; 2016 Feb; 24(4):545-53. PubMed ID: 26732532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural and engineered plasmin inhibitors: applications and design strategies.
    Swedberg JE; Harris JM
    Chembiochem; 2012 Feb; 13(3):336-48. PubMed ID: 22238174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents.
    Longstaff C
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):537-42. PubMed ID: 7531000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin.
    Aoki N; Moroi M; Tachiya K
    Thromb Haemost; 1978 Feb; 39(1):22-31. PubMed ID: 77050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen-plasmin system IX. Specific binding of tranexamic acid to plasmin.
    Iwamoto M
    Thromb Diath Haemorrh; 1975 Jun; 33(3):573-85. PubMed ID: 125463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assay of functional plasminogen in rat plasma applicable to experimental studies of thrombolysis.
    Bangert K; Thorsen S
    Thromb Haemost; 2000 Aug; 84(2):299-306. PubMed ID: 10959704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin.
    Hunt JA; Petteway SR; Scuderi P; Novokhatny V
    Thromb Haemost; 2008 Sep; 100(3):413-9. PubMed ID: 18766256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibitors of the serine protease plasmin: probing the S3 and S3' subsites using a combinatorial library.
    Xue F; Seto CT
    J Med Chem; 2005 Nov; 48(22):6908-17. PubMed ID: 16250649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human plasminogen catalytic domain undergoes an unusual conformational change upon activation.
    Wang X; Terzyan S; Tang J; Loy JA; Lin X; Zhang XC
    J Mol Biol; 2000 Jan; 295(4):903-14. PubMed ID: 10656799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of tripeptidic plasmin inhibitors with nitrile as warhead.
    Teno N; Otsubo T; Gohda K; Wanaka K; Sueda T; Ikeda K; Hijikata-Okunomiya A; Tsuda Y
    J Pept Sci; 2012 Oct; 18(10):620-5. PubMed ID: 22961872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vitro study of the effects of t-PA and tranexamic acid on whole blood coagulation and fibrinolysis.
    Godier A; Parmar K; Manandhar K; Hunt BJ
    J Clin Pathol; 2017 Feb; 70(2):154-161. PubMed ID: 27445340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action.
    Sharma MR; Rothman V; Tuszynski GP; Sharma MC
    Exp Mol Pathol; 2006 Oct; 81(2):136-45. PubMed ID: 16643891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the structure and function of the plasminogen/plasmin system.
    Law RH; Abu-Ssaydeh D; Whisstock JC
    Curr Opin Struct Biol; 2013 Dec; 23(6):836-41. PubMed ID: 24252474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring inhibitor binding at the S' subsites of cathepsin L.
    Chowdhury SF; Joseph L; Kumar S; Tulsidas SR; Bhat S; Ziomek E; Ménard R; Sivaraman J; Purisima EO
    J Med Chem; 2008 Mar; 51(5):1361-8. PubMed ID: 18278855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmin generation induces neutrophil aggregation: dependence on the catalytic and lysine binding sites.
    Ryan TJ; Lai L; Malik AB
    J Cell Physiol; 1992 May; 151(2):255-61. PubMed ID: 1533399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.